Medtronic (MDT, Financial) traded lower in pre-market hours Tuesday, down 4.54% to $88.60 as of 08:20 AM ET, despite reaffirming its full-year guidance alongside its Q3 FY25 results.
The MedTech giant maintained its FY25 organic revenue growth forecast of 4.75% - 5% and projected diluted non-GAAP EPS between $5.44 - $5.50, aligning with the $5.45 consensus estimate.
However, the company missed Street expectations on revenue, largely due to a decline in its Medical-Surgical Portfolio, which reported $2.072 billion, down ~2% YoY and below the $2.14 billion consensus. Meanwhile, its Cardiovascular Portfolio grew ~4% YoY to $3.037 billion, in line with estimates, while the Neuroscience Portfolio exceeded forecasts with $2.458 billion in revenue, also up ~4% YoY.
Medtronic's Diabetes segment outperformed expectations, bringing in $694 million, an ~8% YoY increase. The company's total revenue rose ~3% YoY to $8.3 billion for the quarter.
On the profitability front, adjusted gross margin improved by 50 basis points to 66.6%, while operating margin rose 100 basis points to 26.2%, surpassing analyst forecasts. Adjusted EPS climbed ~7% YoY to $1.39.
Despite a market opportunity in pulse field ablation systems following Johnson & Johnson's (JNJ) temporary halt of its Varipulse rollout, Medtronic's stock remains under pressure in early trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.